What question did this study set out to answer?

This research aims to evaluate the effectiveness of saliva-based liquid biopsy for genotyping TP53 codon 72 polymorphism in oral cancer.

synapse

⌘+K

synapse

⌘+K

March 28, 2026Open Access

Liquid biopsy in oral cancer: Detection of TP53 codon 72 polymorphism in saliva

Key Points

This research aims to evaluate the effectiveness of saliva-based liquid biopsy for genotyping TP53 codon 72 polymorphism in oral cancer.
Collected 33 pre-surgical saliva samples and matched tissue samples.
Extracted cell-free DNA from saliva for analysis.
Used digital droplet PCR (ddPCR) to detect TP53 codon 72 polymorphism.
Compared genotyping results with tissue DNA.
Identified genotypes: C/G (45.5%), G/G (36.3%), and C/C (18.2%).
Observed strong concordance between salivary cfDNA and tissue DNA.
Confirmed saliva as a reliable source for TP53 genotyping.

Abstract

Background: Saliva-based liquid biopsy offers non-invasive genotyping for OSCC. Methods: 33 pre-surgical saliva samples and matched tissue samples. Extracted salivary cell-free DNA; TP53 codon 72 polymorphism (c.215C>G) detected by ddPCR and compared with tissue DNA. Results: Genotypes: C/G 45.5%, G/G 36.3%, C/C 18.2%. Concordance observed between salivary cfDNA and tissue DNA. Conclusion: Saliva is a reliable source for TP53 codon 72 genotyping; supports feasibility of saliva liquid biopsy in OSCC.

Liquid biopsy in oral cancer: Detection of TP53 codon 72 polymorphism in saliva

Key Points

Abstract

Cite This Study